Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-06-2021 | Schizophrenia | Original Paper

Serum zonulin and claudin-5 levels in patients with schizophrenia

Authors: Ayşe Usta, Faruk Kılıç, Arif Demirdaş, Ümit Işık, Duygu Kumbul Doğuç, Mustafa Bozkurt

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2021

Abstract

The aim of this research was to assess whether or not changes in the concentrations of serum zonulin and claudin-5 in patients with schizophrenia could have etiopathogenetic importance. In previous studies, the data regarding the relationship between intestinal and blood–brain barrier (BBB) permeability and the etiology of schizophrenia have been limited. In this study, we assumed that there may be a difference in serum zonulin and claudin-5 levels in patients with schizophrenia, which may affect the severity of the disease. Fifty schizophrenia patients and 50 healthy controls were included in this study. The patients were administered the Positive Symptoms Assessment Scale (SAPS) and Negative Symptoms Assessment Scale (SANS) to determine the severity of symptoms. Venous blood samples were collected, and the serum zonulin and claudin-5 levels were measured. The mean serum zonulin levels were significantly increased in patients with schizophrenia when compared to the control group. Serum claudin-5 levels were decreased in the schizophrenia patients when compared to the controls. The present study indicates that zonulin is increased and claudin-5 is decreased in patients with schizophrenia. These findings extend the existing knowledge on the dysregulation of intestinal permeability, especially zonulin, and BBB, especially claudin-5, and show that both proteins may be involved in the etiopathogenesis of schizophrenia.

Andreasen NC (1990) Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 24:73–88. https://doi.org/10.1159/000418013CrossRefPubMed

Arinami T (2006) Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J Hum Genet 51:1037–1045. https://doi.org/10.1007/s10038-006-0058-5CrossRefPubMed

Asmar RE, Panigrahi P, Bamford P et al (2002) Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 123:1607–1615. https://doi.org/10.1053/gast.2002.36578CrossRefPubMed

Barber GS, Sturgeon C, Fasano A et al (2019) Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia. Schizophr Res 211:111–112. https://doi.org/10.1016/j.schres.2019.07.006CrossRefPubMed

Bassett AS, Chow EWC (2008) Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10:148–157CrossRef

Drago S, El Asmar R, Di Pierro M et al (2006) Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 41:408–419. https://doi.org/10.1080/00365520500235334CrossRefPubMed

Erkoç Ş, Arkonac O, Ataklı C, Özmen E (1991) Pozitif Semptomları Değerlendirme Ölçeğinin Güvenilirliği ve Geçerliliği. Dusunen Adam 4:20–24

Erkoç Ş, Arkonac O, Ataklı C, Özmen E (1991) Negatif Semptomları Değerlendirme Ölçeğinin Güvenilirliği ve Geçerliliği. Dusunen Adam 4:14–15

Esnafoglu E, Cırrık S, Ayyıldız SN et al (2017) Increased serum zonulin levels as an intestinal permeability marker in autistic subjects. J Pediatr 188:240–244. https://doi.org/10.1016/j.jpeds.2017.04.004CrossRefPubMed

10.

Fasano A (2011) Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 91:151–175. https://doi.org/10.1152/physrev.00003.2008CrossRefPubMed

11.

Fasano A (2012) Zonulin, regulation of tight junctions, and autoimmune diseases. Ann NY Acad Sci 1258:25–33. https://doi.org/10.1111/j.1749-6632.2012.06538.xCrossRefPubMed

12.

Fasano A, Hill I (2017) Serum Zonulin, Gut Permeability, and the pathogenesis of autism spectrum disorders: cause, effect, or an epiphenomenon? J Pediatr 188:15–17. https://doi.org/10.1016/j.jpeds.2017.05.038CrossRefPubMed

13.

Fasano A, Uzzau S, Fiore C, Margaretten K (1997) The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 112:839–846. https://doi.org/10.1053/gast.1997.v112.pm9041245CrossRefPubMed

14.

Greene C, Hanley N, Campbell M (2019) Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS 16:3. https://doi.org/10.1186/s12987-019-0123-zCrossRefPubMedPubMedCentral

15.

Greene C, Kealy J, Humphries MM et al (2018) Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry 23:2156–2166. https://doi.org/10.1038/mp.2017.156CrossRefPubMed

16.

Harrison PJ, Owen MJ (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417–419. https://doi.org/10.1016/S0140-6736(03)12379-3CrossRefPubMed

17.

Ishiguro H, Imai K, Koga M et al (2008) Replication study for associations between polymorphisms in the CLDN5 and DGCR2 genes in the 22q11 deletion syndrome region and schizophrenia. Psychiatr Genet 18:255–256CrossRef

18.

Işık Ü, Aydoğan Avşar P, Aktepe E et al (2020) Serum zonulin and claudin-5 levels in children with obsessive–compulsive disorder. Nord J Psychiatry. https://doi.org/10.1080/08039488.2020.1715474CrossRefPubMed

19.

Julio-Pieper M, Bravo JA, Aliaga E et al (2014) Review article: intestinal barrier dysfunction and central nervous system disorders–a controversial association. Aliment Pharmacol Ther 40:1187–1201CrossRef

20.

Keaney J, Walsh DM, O’Malley T et al (2015) Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier. Sci Adv 1:e1500472. https://doi.org/10.1126/sciadv.1500472CrossRefPubMedPubMedCentral

21.

Kelly CP, Green PHR, Murray JA et al (2013) Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 37:252–262. https://doi.org/10.1111/apt.12147CrossRefPubMed

22.

Kılıç F, Işık Ü, Demirdaş A et al (2020) Serum zonulin and claudin-5 levels in patients with bipolar disorder. J Affect Disord 266:37–42. https://doi.org/10.1016/j.jad.2020.01.117CrossRefPubMed

23.

Leffler DA, Kelly CP, Abdallah HZ et al (2012) a randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 107:1554–1562. https://doi.org/10.1038/ajg.2012.211CrossRefPubMedPubMedCentral

24.

Linninge C, Jönsson P, Bolinsson H et al (2018) Effects of acute stress provocation on cortisol levels, zonulin and inflammatory markers in low- and high-stressed men. Biol Psychol 138:48–55. https://doi.org/10.1016/J.BIOPSYCHO.2018.08.013CrossRefPubMed

25.

Maes M, Sirivichayakul S, Kanchanatawan B, Vodjani A (2019) Upregulation of the intestinal paracellular pathway with breakdown of tight and adherens junctions in deficit schizophrenia. Mol Neurobiol. https://doi.org/10.1007/s12035-019-1578-2CrossRefPubMedPubMedCentral

26.

McDonald C, Murray RM (2000) Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 31(2–3):130–137. https://doi.org/10.1016/s0165-0173(99)00030-2CrossRefPubMed

27.

McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76. https://doi.org/10.1093/epirev/mxn001CrossRefPubMed

28.

Menard C, Pfau ML, Hodes GE et al (2017) Social stress induces neurovascular pathology promoting depression. Nat Neurosci 20:1752–1760. https://doi.org/10.1038/s41593-017-0010-3CrossRefPubMedPubMedCentral

29.

Moreno-Navarrete JM, Sabater M, Ortega F et al (2012) Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS ONE 7:e37160. https://doi.org/10.1371/journal.pone.0037160CrossRefPubMedPubMedCentral

30.

Nishiura K, Ichikawa-Tomikawa N, Sugimoto K et al (2017) PKA activation and endothelial claudin-5 breakdown in the schizophrenic prefrontal cortex. Oncotarget 8:93382–93391. https://doi.org/10.18632/oncotarget.21850CrossRefPubMedPubMedCentral

31.

Nitta T, Hata M, Gotoh S et al (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161:653–660. https://doi.org/10.1083/jcb.200302070CrossRefPubMedPubMedCentral

32.

Omidinia E, Mashayekhi Mazar F, Shahamati P et al (2014) Polymorphism of the CLDN5 gene and schizophrenia in an Iranian population. Iran J Public Health 43:79–83PubMedPubMedCentral

33.

Özyurt G, Öztürk Y, Appak YÇ et al (2018) Increased zonulin is associated with hyperactivity and social dysfunctions in children with attention deficit hyperactivity disorder. Compr Psychiatry 87:138–142. https://doi.org/10.1016/j.comppsych.2018.10.006CrossRefPubMed

34.

Rahman MT, Ghosh C, Hossain M et al (2018) IFN-γ IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases. Biochem Biophys Res Commun 507:274–279. https://doi.org/10.1016/j.bbrc.2018.11.021CrossRefPubMed

35.

Severance EG, Dickerson FB, Yolken RH (2018) Autoimmune phenotypes in schizophrenia reveal novel treatment targets. Pharmacol Ther 189:184–198. https://doi.org/10.1016/j.pharmthera.2018.05.005CrossRefPubMedPubMedCentral

36.

Sun Z-Y, Wei J, Xie L et al (2004) The CLDN5 locus may be involved in the vulnerability to schizophrenia. Eur Psychiatry 19:354–357. https://doi.org/10.1016/j.eurpsy.2004.06.007CrossRefPubMed

37.

Tripathi A, Lammers KM, Goldblum S et al (2009) Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 106:16799–16804. https://doi.org/10.1073/pnas.0906773106CrossRefPubMed

38.

Tsukita S, Furuse M (2002) Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol 14:531–536. https://doi.org/10.1016/S0955-0674(02)00362-9CrossRefPubMed

39.

Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809. https://doi.org/10.1038/nri2653CrossRefPubMed

40.

Wei J, Hemmings GP (2005) Gene, gut and schizophrenia: the meeting point for the gene-environment interaction in developing schizophrenia. Med Hypotheses 64:547–552. https://doi.org/10.1016/j.mehy.2004.08.011CrossRefPubMed

41.

Wen L, Ley RE, Volchkov PY et al (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455:1109–1113. https://doi.org/10.1038/nature07336CrossRefPubMedPubMedCentral

42.

Yücel M, Kotan D, Çiftçi GG et al (2016) Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci 20:930–936PubMed

43.

Zhang D, Zhang L, Zheng Y et al (2014) Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract 106:312–318. https://doi.org/10.1016/j.diabres.2014.08.017CrossRefPubMed

Title: Serum zonulin and claudin-5 levels in patients with schizophrenia
Authors: Ayşe Usta
Faruk Kılıç
Arif Demirdaş
Ümit Işık
Duygu Kumbul Doğuç
Mustafa Bozkurt
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keyword: Schizophrenia
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2021
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-020-01152-9

At a glance: The STEP trials

Springer Medicine

Serum zonulin and claudin-5 levels in patients with schizophrenia

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Genetic risks of schizophrenia identified in a matched case–control study

Anomalous self-experiences are related to general cognition deficits in schizophrenia

White matter microstructure in schizophrenia patients with a history of violence

Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions

The network structure of schizotypy in the general population

Meta-analysis of cognitive functioning in patients with psychotic disorders and obsessive–compulsive symptoms